The Evolving Role of Chemotherapy for Hormone-Sensitive Prostate Cancer

Christopher Sweeney, MBBS, medical oncologist, Dana-Farber Cancer Institute, discusses the evolving role of chemotherapy for hormone-sensitive prostate cancer.

Clinical Pearls

Christopher Sweeney, MBBS, medical oncologist, Dana-Farber Cancer Institute, discusses the evolving role of chemotherapy for hormone-sensitive prostate cancer.

  • Oncologists have been trained in the use of chemotherapy — they are aware of the side effects.
  • The side effect profile of chemotherapy is essentially the same as when used for castration-resistant disease.
  • The question remains: Is there a difference in using docetaxel in the hormone-sensitive or castration-resistant settings?
  • The rate of neutropenic fever was slightly higher in the CHAARTED study (8%) compared with the TAX 327 study (3%).